Bird Rock Bio

Today we announced progress toward clinical trials with our second drug candidate, namacizumab, a novel therapeutic designed to slow or halt progression of #NASH and diabetic nephropathy. Read more here: http://bit.ly/2fc6AnR

In the News: Unique Antibody Therapeutic for #NASH - Drug Discovery News chats with CEO, Paul Grayson, to learn more. http://bit.ly/2kMnTOP

Johnson & Johnson Innovation has grabbed Bird Rock Bio's experimental #NASH drug, namacizumab http://bit.ly/2ifGDkh

FierceBiotech reports - Johnson & Johnson Innovation takes on Bird Rock Bio's NASH candidate with biotech buyout option - http://bit.ly/2hVs1KO

Bird Rock Bio Receives Approval From Anvisa And Conep To Initiate The First Phase 2 Study In Brazil Of Gerilimzumab For Rheumatoid Arthritis

Today we announced progress toward clinical trials with our second drug candidate, namacizumab, a novel therapeutic designed to slow or halt progression of #NASH and diabetic nephropathy. Read more here: http://bit.ly/2fc6AnR

Clinical data supports $2K #drugpricing for novel biologic therapy in development to treat #rheumatoidarthritis, potential for global access http://bit.ly/1S3qriJ

Thanks Levine Media Group for the discussion. #Rheumatoidarthritis is one of the most underserved diseases globally. We hope that through innovation we can bring an affordable best-in-class therapy to patients around the world.